About Alkermes Plc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: IE
- Website: https://www.alkermes.com/
Frequently Asked Questions
What is the 52-week range for ALKS?
The 52-week high is $55.67 and the 52-week low is $27.
What is the P/E ratio for ALKS?
The Price to Earnings (P/E) ratio is 105.93.
What is the dividend yield for ALKS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 3.72%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 3.97%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.54.
Analyst Recommendation Trends
Wall Street analyst consensus for ALKS over the last few months:
Latest ALKS News
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver
Alkermes could surge as LUMRYZ expands into idiopathic hypersomnia after Phase 3 wins, boosting EBITDA despite future royalties. Read more on ALKS stock here.
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]
Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...
Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)
Alkermes' pipeline, notably alixorexton for narcolepsy and ALKS-7290 for ADHD, faces strong competition. Read why ALKS stock is downgraded to a hold.
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's conf
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target
RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.
Baird Maintains Outperform on Alkermes, Raises Price Target to $61
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $58 to $61.
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290
Alkermes plc (NASDAQ:ALKS) shares gained 6. 5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD).
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
DUBLIN, September 21, 2026--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n
Needham Reiterates Buy on Alkermes, Maintains $62 Price Target
Needham analyst Ami Fadia reiterates Alkermes (NASDAQ:ALKS) with a Buy and maintains $62 price target.
Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients
Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
DUBLIN, September 16, 2026--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations.
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes plc upgraded to Buy on strong revenue growth, Lumryz momentum, and orexin pipeline upside in sleep/CNSâclick to get the latest ALKS outlook now.
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
DUBLIN, September 10, 2026--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-10-02 | Gaffin David Joseph | -2,034 | $41.03 | $83,455 |
| 2026-09-03 | Gaffin David Joseph | -2,034 | $48.01 | $97,652 |
| 2026-09-01 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-09-01 | Hopkinson Craig C. | -9,000 | $46.986 | $422,874 |
| 2026-09-01 | Hopkinson Craig C. | +5,000 | $24.59 | $122,950 |
| 2026-08-17 | Nichols Christian Todd | -664 | $49.6526 | $32,969 |
| 2026-08-17 | Nichols Christian Todd | -6,912 | $49.1851 | $339,967 |
| 2026-08-05 | Jackson Blair Curtis | +124,305 | - | - |
| 2026-08-05 | Jackson Blair Curtis | +93,229 | - | - |
| 2026-08-03 | snyderman nancy lynn MD | -16,524 | - | - |
| 2026-08-03 | snyderman nancy lynn MD | -27,948 | - | - |
| 2026-08-03 | snyderman nancy lynn MD | -44,472 | $50.348 | $2,239,076 |
| 2026-08-03 | snyderman nancy lynn MD | +16,524 | $46.72 | $772,001 |
| 2026-08-03 | snyderman nancy lynn MD | +27,948 | $46.72 | $1,305,731 |
| 2026-08-03 | Hopkinson Craig C. | -4,896 | - | - |
| 2026-08-03 | Hopkinson Craig C. | -104 | - | - |
| 2026-08-03 | Hopkinson Craig C. | -9,000 | $48.58 | $437,220 |
| 2026-08-03 | Hopkinson Craig C. | +4,896 | $24.59 | $120,393 |
| 2026-08-03 | Hopkinson Craig C. | +104 | $19.34 | $2,011 |
| 2026-08-03 | Gaffin David Joseph | -2,034 | $48.58 | $98,812 |
| 2026-07-06 | Gaffin David Joseph | -2,034 | $54.03 | $109,897 |
| 2026-07-01 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-07-01 | Hopkinson Craig C. | -700 | $52.1314 | $36,492 |
| 2026-07-01 | Hopkinson Craig C. | -8,300 | $51.4613 | $427,129 |
| 2026-07-01 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-06-12 | Wright Christopher I | -2,000 | $45.1 | $90,200 |
| 2026-06-04 | Gaffin David Joseph | -2,034 | $43.05 | $87,564 |
| 2026-06-01 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-06-01 | Hopkinson Craig C. | -9,000 | $41.6715 | $375,044 |
| 2026-06-01 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-05-29 | Parisi Samuel Joseph | -12,825 | - | - |
| 2026-05-29 | Parisi Samuel Joseph | -3,392 | - | - |
| 2026-05-29 | Parisi Samuel Joseph | -16,217 | $42.3634 | $687,007 |
| 2026-05-29 | Parisi Samuel Joseph | +12,825 | $19.34 | $248,036 |
| 2026-05-29 | Parisi Samuel Joseph | +3,392 | $20.03 | $67,942 |
| 2026-05-21 | Wright Christopher I | -6,142 | - | - |
| 2026-05-21 | Wright Christopher I | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | Wright Christopher I | +6,142 | - | - |
| 2026-05-21 | snyderman nancy lynn MD | -6,142 | - | - |
| 2026-05-21 | snyderman nancy lynn MD | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | snyderman nancy lynn MD | +6,142 | - | - |
| 2026-05-21 | GAYNOR RICHARD | -6,142 | - | - |
| 2026-05-21 | GAYNOR RICHARD | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | GAYNOR RICHARD | +6,142 | - | - |
| 2026-05-21 | Cooke Shane | -6,142 | - | - |
| 2026-05-21 | Cooke Shane | -3,207 | $36.95 | $118,499 |
| 2026-05-21 | Cooke Shane | +6,142 | - | - |
| 2026-05-21 | Wilson Frank Anders | -6,142 | - | - |
| 2026-05-21 | Wilson Frank Anders | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | Wilson Frank Anders | +6,142 | - | - |
| 2026-05-21 | Lurker Nancy | -6,142 | - | - |
| 2026-05-21 | Lurker Nancy | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | Lurker Nancy | +6,142 | - | - |
| 2026-05-21 | LAURENCIN CATO T | -6,142 | - | - |
| 2026-05-21 | LAURENCIN CATO T | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | LAURENCIN CATO T | +6,142 | - | - |
| 2026-05-21 | MCKEON BRIAN P | -6,142 | - | - |
| 2026-05-21 | MCKEON BRIAN P | -1,475 | $36.95 | $54,501 |
| 2026-05-21 | MCKEON BRIAN P | +6,142 | - | - |
| 2026-05-20 | GAYNOR RICHARD | +5,409 | - | - |
| 2026-05-20 | GAYNOR RICHARD | +11,538 | - | - |
| 2026-05-20 | Cooke Shane | +5,409 | - | - |
| 2026-05-20 | Cooke Shane | +11,538 | - | - |
| 2026-05-20 | Wright Christopher I | +5,409 | - | - |
| 2026-05-20 | Wright Christopher I | +11,538 | - | - |
| 2026-05-20 | snyderman nancy lynn MD | +5,409 | - | - |
| 2026-05-20 | snyderman nancy lynn MD | +11,538 | - | - |
| 2026-05-20 | GAYNOR RICHARD | +5,409 | - | - |
| 2026-05-20 | GAYNOR RICHARD | +11,538 | - | - |
| 2026-05-20 | Cooke Shane | +5,409 | - | - |
| 2026-05-20 | Cooke Shane | +11,538 | - | - |
| 2026-05-20 | Wilson Frank Anders | +5,409 | - | - |
| 2026-05-20 | Wilson Frank Anders | +11,538 | - | - |
| 2026-05-20 | Lurker Nancy | +5,409 | - | - |
| 2026-05-20 | Lurker Nancy | +11,538 | - | - |
| 2026-05-20 | LAURENCIN CATO T | +5,409 | - | - |
| 2026-05-20 | LAURENCIN CATO T | +11,538 | - | - |
| 2026-05-20 | MCKEON BRIAN P | +5,409 | - | - |
| 2026-05-20 | MCKEON BRIAN P | +11,538 | - | - |
| 2026-05-04 | Gaffin David Joseph | -2,034 | $33.2 | $67,529 |
| 2026-05-01 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-05-01 | Hopkinson Craig C. | -9,000 | $33.3955 | $300,560 |
| 2026-05-01 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-04-11 | Lurker Nancy | -3,751 | - | - |
| 2026-04-11 | Lurker Nancy | -901 | $33.36 | $30,057 |
| 2026-04-11 | Lurker Nancy | +3,751 | - | - |
| 2026-04-06 | Gaffin David Joseph | -2,034 | $34.57 | $70,315 |
| 2026-04-01 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-04-01 | Hopkinson Craig C. | -9,000 | $35.5116 | $319,604 |
| 2026-04-01 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-03-03 | Gaffin David Joseph | -2,034 | $29.76 | $60,532 |
| 2026-03-02 | Reed Joshua | +30,854 | - | - |
| 2026-03-02 | Reed Joshua | +66,430 | - | - |
| 2026-03-02 | Parisi Samuel Joseph | +14,176 | - | - |
| 2026-03-02 | Parisi Samuel Joseph | +15,033 | - | - |
| 2026-03-02 | Parisi Samuel Joseph | -6,890 | $29.29 | $201,808 |
| 2026-03-02 | Nichols Christian Todd | +30,854 | - | - |
| 2026-03-02 | Nichols Christian Todd | +66,430 | - | - |
| 2026-03-02 | Nichols Christian Todd | -6,000 | $30 | $180,000 |
| 2026-03-02 | Jackson Blair Curtis | +44,078 | - | - |
| 2026-03-02 | Jackson Blair Curtis | +94,900 | - | - |
| 2026-03-02 | Hopkinson Craig C. | +38,568 | - | - |
| 2026-03-02 | Hopkinson Craig C. | +83,037 | - | - |
| 2026-03-02 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-03-02 | Hopkinson Craig C. | -9,000 | $29.7206 | $267,485 |
| 2026-03-02 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-03-02 | Gaffin David Joseph | +36,364 | - | - |
| 2026-03-02 | Gaffin David Joseph | +78,292 | - | - |
| 2026-03-02 | Gaffin David Joseph | -2,034 | $29.29 | $59,576 |
| 2026-03-02 | POPS RICHARD F | +88,843 | - | - |
| 2026-02-26 | Nichols Christian Todd | -5,410 | - | - |
| 2026-02-26 | Nichols Christian Todd | -2,403 | $30.73 | $73,844 |
| 2026-02-26 | Nichols Christian Todd | +5,410 | - | - |
| 2026-02-26 | Jackson Blair Curtis | -8,322 | - | - |
| 2026-02-26 | Jackson Blair Curtis | -3,695 | $30.73 | $113,547 |
| 2026-02-26 | Jackson Blair Curtis | +8,322 | - | - |
| 2026-02-26 | Parisi Samuel Joseph | -2,747 | - | - |
| 2026-02-26 | Parisi Samuel Joseph | -808 | $30.73 | $24,830 |
| 2026-02-26 | Parisi Samuel Joseph | +2,747 | - | - |
| 2026-02-26 | Hopkinson Craig C. | -6,866 | - | - |
| 2026-02-26 | Hopkinson Craig C. | -3,049 | $30.73 | $93,696 |
| 2026-02-26 | Hopkinson Craig C. | +6,866 | - | - |
| 2026-02-26 | Gaffin David Joseph | -6,866 | - | - |
| 2026-02-26 | Gaffin David Joseph | -3,049 | $30.73 | $93,696 |
| 2026-02-26 | Gaffin David Joseph | +6,866 | - | - |
| 2026-02-23 | Parisi Samuel Joseph | -2,283 | - | - |
| 2026-02-23 | Parisi Samuel Joseph | -672 | $32.19 | $21,632 |
| 2026-02-23 | Parisi Samuel Joseph | +2,283 | - | - |
| 2026-02-23 | Nichols Christian Todd | -6,407 | - | - |
| 2026-02-23 | Nichols Christian Todd | -2,845 | $32.19 | $91,581 |
| 2026-02-23 | Nichols Christian Todd | +6,407 | - | - |
| 2026-02-23 | Jackson Blair Curtis | -8,738 | - | - |
| 2026-02-23 | Jackson Blair Curtis | -3,880 | $32.19 | $124,897 |
| 2026-02-23 | Jackson Blair Curtis | +8,738 | - | - |
| 2026-02-23 | Hopkinson Craig C. | -7,689 | - | - |
| 2026-02-23 | Hopkinson Craig C. | -3,414 | $32.19 | $109,897 |
| 2026-02-23 | Hopkinson Craig C. | +7,689 | - | - |
| 2026-02-23 | Gaffin David Joseph | -7,689 | - | - |
| 2026-02-23 | Gaffin David Joseph | -3,414 | $32.19 | $109,897 |
| 2026-02-23 | Gaffin David Joseph | +7,689 | - | - |
| 2026-02-19 | Parisi Samuel Joseph | -2,991 | - | - |
| 2026-02-19 | Parisi Samuel Joseph | -979 | $32 | $31,328 |
| 2026-02-19 | Parisi Samuel Joseph | +2,991 | - | - |
| 2026-02-19 | Nichols Christian Todd | -6,045 | - | - |
| 2026-02-19 | Nichols Christian Todd | -2,277 | $32 | $72,864 |
| 2026-02-19 | Nichols Christian Todd | +6,045 | - | - |
| 2026-02-19 | Jackson Blair Curtis | -9,300 | - | - |
| 2026-02-19 | Jackson Blair Curtis | -4,130 | $32 | $132,160 |
| 2026-02-19 | Jackson Blair Curtis | +9,300 | - | - |
| 2026-02-19 | Hopkinson Craig C. | -7,673 | - | - |
| 2026-02-19 | Hopkinson Craig C. | -3,407 | $32 | $109,024 |
| 2026-02-19 | Hopkinson Craig C. | +7,673 | - | - |
| 2026-02-19 | Gaffin David Joseph | -7,673 | - | - |
| 2026-02-19 | Gaffin David Joseph | -3,407 | $32 | $109,024 |
| 2026-02-19 | Gaffin David Joseph | +7,673 | - | - |
| 2026-02-18 | Parisi Samuel Joseph | -2,034 | - | - |
| 2026-02-18 | Parisi Samuel Joseph | -706 | $32.02 | $22,606 |
| 2026-02-18 | Parisi Samuel Joseph | +2,034 | - | - |
| 2026-02-18 | Nichols Christian Todd | -6,355 | - | - |
| 2026-02-18 | Nichols Christian Todd | -1,869 | $32.02 | $59,845 |
| 2026-02-18 | Nichols Christian Todd | +6,355 | - | - |
| 2026-02-18 | Jackson Blair Curtis | -8,897 | - | - |
| 2026-02-18 | Jackson Blair Curtis | -3,796 | $32.02 | $121,548 |
| 2026-02-18 | Jackson Blair Curtis | +8,897 | - | - |
| 2026-02-18 | Hopkinson Craig C. | -8,897 | - | - |
| 2026-02-18 | Hopkinson Craig C. | -3,504 | $32.02 | $112,198 |
| 2026-02-18 | Hopkinson Craig C. | +8,897 | - | - |
| 2026-02-18 | Gaffin David Joseph | -6,355 | - | - |
| 2026-02-18 | Gaffin David Joseph | -2,126 | $32.02 | $68,075 |
| 2026-02-18 | Gaffin David Joseph | +6,355 | - | - |
| 2026-02-05 | Nichols Christian Todd | -6,389 | $33.55 | $214,351 |
| 2026-02-05 | Nichols Christian Todd | +21,127 | - | - |
| 2026-02-05 | Jackson Blair Curtis | -8,626 | $33.55 | $289,402 |
| 2026-02-05 | Jackson Blair Curtis | +28,810 | - | - |
| 2026-02-05 | Hopkinson Craig C. | -7,454 | $33.55 | $250,082 |
| 2026-02-05 | Hopkinson Craig C. | +25,352 | - | - |
| 2026-02-05 | Gaffin David Joseph | -7,619 | $33.55 | $255,617 |
| 2026-02-05 | Gaffin David Joseph | +25,352 | - | - |
| 2026-02-05 | POPS RICHARD F | -62,230 | $33.55 | $2,087,816 |
| 2026-02-05 | POPS RICHARD F | +149,580 | - | - |
| 2026-02-02 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-02-02 | Hopkinson Craig C. | -4,000 | $33.54 | $134,160 |
| 2026-02-02 | Hopkinson Craig C. | -5,000 | $34.2449 | $171,225 |
| 2026-02-02 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-02-02 | Cooke Shane | -61,200 | - | - |
| 2026-02-02 | Cooke Shane | -32,113 | $34.7796 | $1,116,877 |
| 2026-02-02 | Cooke Shane | -29,087 | $34.3382 | $998,795 |
| 2026-02-02 | Cooke Shane | +61,200 | $31.64 | $1,936,368 |
| 2026-01-08 | Hopkinson Craig C. | -5,000 | - | - |
| 2026-01-08 | Hopkinson Craig C. | -5,000 | $30.001 | $150,005 |
| 2026-01-08 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2026-01-02 | Hopkinson Craig C. | -4,000 | $28 | $112,000 |
| 2025-12-03 | Hopkinson Craig C. | -3,748 | - | - |
| 2025-12-03 | Hopkinson Craig C. | -3,748 | $30.0019 | $112,447 |
| 2025-12-03 | Hopkinson Craig C. | +3,748 | $19.34 | $72,486 |
| 2025-12-01 | Hopkinson Craig C. | -4,000 | $29.3 | $117,200 |
| 2025-11-03 | Hopkinson Craig C. | -5,000 | - | - |
| 2025-11-03 | Hopkinson Craig C. | -9,000 | $30.3824 | $273,442 |
| 2025-11-03 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2025-10-15 | Hopkinson Craig C. | -5,000 | - | - |
| 2025-10-15 | Hopkinson Craig C. | -9,000 | $31.5307 | $283,776 |
| 2025-10-15 | Hopkinson Craig C. | +5,000 | $19.34 | $96,700 |
| 2025-10-08 | Reed Joshua | +36,656 | - | - |
| 2025-10-08 | Reed Joshua | +158,743 | - | - |